Table 2 KEGG pathway analysis of aberrantly methylated-differentially expressed genes in hepatocellular carcinoma
From: DNA methylation biomarkers for hepatocellular carcinoma
| Pathway ID | Pathway name | Gene count | False discovery rate | Genes |
|---|---|---|---|---|
| Hypomethylation and high expression | ||||
| 4110 | Cell cycle | 12 | 1.03E−15 | ANAPC10, ANAPC4, BUB1, BUB1B, BUB3, CCNB1, CDC16, CDC20, CDC23, MAD1L1, MAD2L1, PTTG1 |
| 4114 | Oocyte meiosis | 10 | 6.60E−13 | ANAPC10, ANAPC4, AURKA, BUB1, CCNB1, CDC16, CDC20, CDC23, MAD2L1, PTTG1 |
| 4914 | Progesterone-mediated oocyte maturation | 8 | 1.84E−10 | ANAPC10, ANAPC4, BUB1, CCNB1, CDC16, CDC23, MAD1L1, MAD2L1 |
| 4120 | Ubiquitin mediated proteolysis | 6 | 1.11E−05 | ANAPC10, ANAPC4, CDC16, CDC20, CDC23, DDB1 |
| 4360 | Axon guidance | 4 | 0.00416 | ROBO1, SLIT1, SLIT2, SLIT3 |
| Hypermethylation and low expression | ||||
| 5200 | Pathways in cancer | 9 | 3.99E−07 | AR, CCND1, CDK4, CDK6, CDKN1A, HHIP, NTRK1, PTCH1, SHH |
| 4115 | p53 signaling pathway | 4 | 0.000145 | CCND1, CDK4, CDK6, CDKN1A |
| 4110 | Cell cycle | 4 | 0.00109 | CCND1, CDK4, CDK6, CDKN1A |
| 4010 | MAPK signaling pathway | 5 | 0.00115 | BDNF, NGF, NTF4, NTRK1, NTRK2 |
| 5205 | Proteoglycans in cancer | 4 | 0.00503 | CCND1, CDKN1A, ESR1, PTCH1 |
